Category

Description

Company Summary

VL58, Inc. is a privately held, early-stage biotechnology company developing a novel approach to gene editing and gene therapy that can address diseases that are untreatable with current approaches like CRISPR or AAVs.

VL58 was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 40 groundbreaking companies over the past fifteen years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Seres Therapeutics (NASDAQ:MCRB), Moderna, Syros Pharmaceuticals (SYRS), Rubius Therapeutics (RUBY), Axcella Health, Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary

The Principal or Associate Director will be responsible for the execution and development of various molecular assay protocols. This individual will join a dynamic, rapidly growing, and highly collaborative team that combines significant biologic drug discovery experience with pioneering discoveries driving a novel biological platform.

Key Responsibilities

• The successful candidate will work both independently and as part of a collaborative team to design, plan and execute experiments that support research activities, project goals, and platform development.
• Oversight of a team of 3-5 scientists and research associates to ensure the development of, and rapid and high-quality execution of molecular assays on candidates
• The team will be responsible for developing and executing assays for:Quantitative PCR and digital droplet PCR

• Next generation sequencing
• ELISAs
• Immunohistochemistry
• Flow cytometry

• Managing external relationships with contract research organizations
• Design, execution, and troubleshooting of experiments as well as data analysis
• Maintaining lab notebooks and reporting data and analysis results to the scientific team

Basic Qualifications

• Ph.D. in molecular biology, biochemistry, genetics, immunology or related field with 5 years of industry experience is required.
• Prior experience with quantitative assessment of on-target/off-target and cell penetrance for gene editing, gene therapy, or RNA interference.
• Proven hands-on experience with molecular biology assays with a variety of readout technologies, such as, but not limited to: quantitative PCR, next generation sequencing, ELISAs
• Proven hands-on experience with cell-based assays, including but not limited to flow cytometry, immunohistochemistry
• Experience independently generating precise, reliable data and skillfully analyzing the data.
• Excellent communication and presentation skills, capable of conveying technical information in a clear and thorough manner.
• A strong self-starter, independent thinker, with a strong attention to detail.
• Excellent communication and presentation skills, capable of conveying technical information in a clear and thorough manner.
• Eager to work with highly-skilled and dynamic teams in a fast-paced, entrepreneurial and technical setting.
• Demonstrated industry experience or academic achievement, as evidenced by publications in high impact journals or drug development is required
• Previous experience managing multiple bench researchers

Preferred Qualifications

• Post-doctoral experience
• Experience with delivery of gene editing, gene therapy, or RNA interference technologies

Get In Touch